Dec. 8 at 1:34 PM
Kamada announced it will discontinue its Phase 3 trial of inhaled AAT for Alpha-1 Antitrypsin Deficiency after an independent monitoring committee determined the study was unlikely to meet its primary endpoint of improving lung function. The company stressed the decision was driven by lack of efficacy, not safety concerns.
Despite the setback, Kamada reaffirmed its 2025 revenue guidance of
$178–
$182 million and adjusted EBITDA of
$40–
$44 million, and projected double-digit growth in 2026 with more detailed guidance coming in January. The CEO said the company remains well positioned for future growth.
Kamada will continue supplying GLASSIA, its IV AAT therapy licensed through Takeda, and noted its portfolio includes six FDA-approved plasma-derived specialty products sold in over 30 countries. The firm said it remains focused on new business development opportunities to support long-term expansion.
$KMDA